CALCIJECT PMD SOLUTION FOR INJECTION

Land: Irland

Sprog: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Aktiv bestanddel:

CALCIUM GLUCONATE, MAGNESIUM HYPOPHOSPHITE, GLUCOSE MONOHYDRATE, BORIC ACID

Tilgængelig fra:

Norbrook Laboratories Limited

ATC-kode:

QA12AA20

INN (International Name):

CALCIUM GLUCONATE, MAGNESIUM HYPOPHOSPHITE, GLUCOSE MONOHYDRATE, BORIC ACID

Dosering:

Unknown

Lægemiddelform:

Solution for Injection

Recept type:

LM-Licensed Merchant

Terapeutisk gruppe:

Ovine

Terapeutisk område:

Calcium (different salts in combination)

Terapeutiske indikationer:

Vitamins & Minerals

Autorisation status:

Authorised

Autorisation dato:

1991-10-01

Produktets egenskaber

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Calciject PMD Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear pale yellow sterile aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Calciject PMD is indicated in the treatment of hypocalcaemia complicated by a deficiency of magnesium with
accompanying hypoglycaemia.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
No special warnings.
Each ml contains:
Active Substance
Calcium Gluconate
166 mg
Boric Acid
34 mg
Dextrose Monohydrate
200 mg
Magnesium Hypophosphite
50 mg
(as hexahydrate)
Excipients
Chlorocresol (as preservative)
1 mg
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 28/08/2014_
_CRN 7013831_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The solution should be warmed to body temperature before administration. Intravenous injections should be given slowly
and stopped at the first signs of adverse reaction. Rapid intravenous injection may result in cardiac arrhythmias and, in
severely toxaemic animals, collapse and death.
As intravenous administration of this product could cause death, this route should only be used by a veterinary surgeon.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Calciject PMD can be safely administered to pregnant and lactating animals.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORM